{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:28:58Z","timestamp":1768274938860,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jiac.2022.08.023","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T23:01:02Z","timestamp":1662418862000},"page":"1645-1653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-5049","authenticated-orcid":false,"given":"Josiane M.","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana M.","family":"Fachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Beraldi-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1168-241X","authenticated-orcid":false,"given":"Allan M.","family":"Junker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-3984","authenticated-orcid":false,"given":"Eric L.","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-1258","authenticated-orcid":false,"given":"Priscila","family":"Imazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.08.023_bib1","series-title":"WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment","author":"World Health Organization WHO","year":"2020"},{"key":"10.1016\/j.jiac.2022.08.023_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1473-3099(18)30157-9","article-title":"Tuberculosis susceptibility and protection in children","volume":"19","author":"Basu Roy","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.5588\/ijtld.10.0555","article-title":"QuantiFERON\u00ae-TB gold in-tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact","volume":"15","author":"Kasambira","year":"2011","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib4","series-title":"Latent tuberculosis infection Updated and consolidated guidelines for programmatic management","author":"World Health Organization WHO","year":"2018"},{"key":"10.1016\/j.jiac.2022.08.023_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0146098","article-title":"The use of interferon gamma inducible protein 10 as a potential biomarker in the diagnosis of latent tuberculosis infection in Uganda","volume":"11","author":"Biraro","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jiac.2022.08.023_bib6","first-page":"42","article-title":"Tuberculosis: immunological aspects in the infection and in the disease","volume":"21","author":"Moutinho","year":"2011","journal-title":"Revista M\u00e9dicina de Minas Gerais"},{"key":"10.1016\/j.jiac.2022.08.023_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pulmoe.2019.06.002","article-title":"Preventive therapy compliance in pediatric tuberculosis \u2013 a single center experience","volume":"26","author":"Santos","year":"2020","journal-title":"Pulmonology"},{"key":"10.1016\/j.jiac.2022.08.023_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12098-010-0257-0","article-title":"A relook at preventive therapy for tuberculosis in children","volume":"78","author":"Singh","year":"2011","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.jiac.2022.08.023_bib9","first-page":"153","article-title":"Epidemiology and disease burden of tuberculosis in children: a global perspective","volume":"7","author":"Seddon","year":"2014","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2022.08.023_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(16)30474-1","article-title":"Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Jenkins","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41479-016-0023-9","article-title":"Tuberculosis exposure, infection and disease in children: a systematic diagnostic approach","volume":"8","author":"Roya-Pabon","year":"2016","journal-title":"Pneumonia"},{"key":"10.1016\/j.jiac.2022.08.023_bib12","series-title":"WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment","author":"World Health Organization WHO","year":"2020"},{"key":"10.1016\/j.jiac.2022.08.023_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-91","article-title":"Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis","volume":"14","author":"Ayieko","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/INF.0000000000001879","article-title":"Isoniazid for the prevention of tuberculosis in HIV-infected children: a systematic review and meta-analysis","volume":"37","author":"Charan","year":"2018","journal-title":"J Pediatr Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib15","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","article-title":"Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review","volume":"22","author":"Hamada","year":"2018","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s12498-013-0067-1","article-title":"Over de grenzen van het medisch beroepsgeheim. Dilemma's rond privacy en vertrouwen in de zorg","volume":"21","author":"Jansen","year":"2013","journal-title":"TBV \u2013 Tijdschr voor Bedrijfs- en Verzek"},{"key":"10.1016\/j.jiac.2022.08.023_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2022.08.023_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2022.08.023_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.jiac.2022.08.023_bib20","first-page":"ED000142","volume":"10","author":"Boutron","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2022.08.023_bib21","first-page":"639","volume":"5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jiac.2022.08.023_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Medical decision making\/jul 2013 641 evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jiac.2022.08.023_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jiac.2022.08.023_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003111","article-title":"Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review","volume":"3","author":"Sobieraj","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2022.08.023_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jiac.2022.08.023_bib26","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Systematic Reviews. BioMed Central"},{"key":"10.1016\/j.jiac.2022.08.023_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jiac.2022.08.023_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jiac.2022.08.023_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: a decision support system for evidence-based medicine","volume":"55","author":"Van Valkenhoef","year":"2013","journal-title":"Decis Support Syst"},{"key":"10.1016\/j.jiac.2022.08.023_bib30","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Oxman","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jiac.2022.08.023_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02713608","article-title":"Ethambutol compared to rifampin in original treatment of pulmonary tuberculosis","volume":"157","author":"Bobrowitz","year":"1980","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.jiac.2022.08.023_bib32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm\/140.4.1001","article-title":"Random variation in tuberculin sensitivity in schoolchildren. Serial skin testing before and after preventive treatment for tuberculosis","volume":"140","author":"Felten","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.jiac.2022.08.023_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/thx.2010.156752","article-title":"The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting","volume":"6","author":"Frigati","year":"2011","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jiac.2022.08.023_bib34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5588\/ijtld.13.0354","article-title":"Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study","volume":"18","author":"Gray","year":"2014","journal-title":"Int J Tubercul Lung Dis : Off. J. Int. Union Against Tuberculosis Lung Dis."},{"issue":"11","key":"10.1016\/j.jiac.2022.08.023_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00006454-199011000-00004","article-title":"A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis","volume":"9","author":"Kumar","year":"1990","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.jiac.2022.08.023_bib36","article-title":"Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules","volume":"17","author":"Le roux","year":"2013","journal-title":"Int J Tubercul Lung Dis : Off. J. Int. Union Against Tuberculosis Lung Dis."},{"key":"10.1016\/j.jiac.2022.08.023_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/adc.36.190.669","article-title":"Isoniazid in primary tuberculosis in infancy, A controlled clinical trial","author":"Lorber","year":"1961","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.jiac.2022.08.023_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200539","article-title":"Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial","volume":"13","author":"Meyvisch","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jiac.2022.08.023_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-018-3070-0","article-title":"Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)","volume":"19","author":"Seddon","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.jiac.2022.08.023_bib40","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jiac.2022.08.023_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/bmj.39000.486400.55","article-title":"Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial","volume":"334","author":"Zar","year":"2007","journal-title":"Br Med J"},{"key":"10.1016\/j.jiac.2022.08.023_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":"Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children","volume":"365","author":"Madhi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.08.023_bib43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jiac.2022.08.023_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM196110122651501","article-title":"Preventive effects of isoniazid in the treatment of primary tuberculosis in children","volume":"265","author":"Mount","year":"1961","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.08.023_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ije\/2.2.153","article-title":"Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969","volume":"2","author":"Debre","year":"1973","journal-title":"Int J Epidemiol"},{"issue":"4 Pt 1","key":"10.1016\/j.jiac.2022.08.023_bib47","first-page":"1376","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2022.08.023_bib48","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21037\/jtd.2017.06.16","article-title":"Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review","volume":"9","author":"D'Ambrosio","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib49","series-title":"The pharmacological basis of therapeutics","author":"Goodman Brunton","year":"2012"},{"key":"10.1016\/j.jiac.2022.08.023_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev.pharmtox.45.120403.100120","article-title":"The magic bullets and tuberculosis drug targets. Annual Review of Pharmacology and Toxicology","volume":"45","author":"Zhang","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jiac.2022.08.023_bib51","first-page":"1413","article-title":"Assessing the combined antibacterial effect of isoniazid and rifampin on four mycobacterium tuberculosis strains using in vitro experiments and response-surface modeling","volume":"62","author":"Genestet","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.08.023_bib52","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ppul.24624","article-title":"Pharmacokinetics of isoniazid in children with tuberculosis\u2014a comparative study at two doses","volume":"55","author":"Shah","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jiac.2022.08.023_bib53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/jac\/dku478","article-title":"Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study","volume":"70","author":"Hiruy","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.08.023_bib54","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.04338-14","article-title":"Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India","volume":"59","author":"Ramachandran","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.08.023_bib55","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5588\/ijtld.15.0288","article-title":"Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children","volume":"20","author":"Mukherjee","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib56","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1513\/AnnalsATS.201905-394OC","article-title":"Temporal factors and missed doses of tuberculosis treatment: a causal associations approach to analyses of digital adherence data","volume":"17","author":"Stagg","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jiac.2022.08.023_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 Months of isoniazid and rifapentine in New York city health department clinics","volume":"62","author":"Stennis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.08.023_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/QAD.0000000000002380","article-title":"Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV","volume":"34","author":"Kendall","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2022.08.023_bib61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.08.023_bib62","series-title":"Sanofi inks pact with Unitaid; to reduce TB drug Rifapentine price by 70%","year":"2019"},{"key":"10.1016\/j.jiac.2022.08.023_bib63","author":"World Health Organization WHO"},{"key":"10.1016\/j.jiac.2022.08.023_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1055\/s-0034-1543955","article-title":"Rifampin use and safety in hospitalized infants on behalf of the best pharmaceuticals for children act-pediatric trials network administrative core committee HHS public access","volume":"32","author":"Arnold","year":"2015","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jiac.2022.08.023_bib65","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.jiac.2022.08.023_bib66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/adc.2010.182600","article-title":"Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children","volume":"95","author":"Bright-Thomas","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jiac.2022.08.023_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14787210.2018.1441025","article-title":"Latent tuberculosis in childhood: tolerability of two different therapeutic approaches","volume":"16","author":"Tersigni","year":"2018","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:22Z","timestamp":1761159862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1341321X22002495"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.08.023","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}